Wongsurakiat P, Chitwarakorn N. Severe community-acquired pneumonia in general medical wards: outcomes and impact of initial antibiotic selection. BMC Pulm Med. 2019;19:179.
PubMed
PubMed Central
Google Scholar
Lanks CW, Musani AI, Hsia DW. Community-acquired pneumonia and hospital-acquired pneumonia. Med Clin N Am. 2019;103:487–501.
PubMed
Google Scholar
Chahin A, Opal SM. Severe pneumonia caused by legionella pneumophila: differential diagnosis and therapeutic considerations. Infect Dis Clin N Am. 2017;31:111–21.
Google Scholar
Marti C, Garin N, Grosgurin O, et al. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care (Lond, Engl). 2012;16:R141.
Google Scholar
Smith HZ, Kendall B. Carbapenem resistant enterobacteriaceae. StatPearls. Treasure Island (FL): StatPearls Publishing. Copyright © 2021, StatPearls Publishing LLC., 2021.
Hraiech S, Alingrin J, Dizier S, et al. Time to intubation is associated with outcome in patients with community-acquired pneumonia. PLoS ONE. 2013;8:e74937.
CAS
PubMed
PubMed Central
Google Scholar
Restrepo MI, Mortensen EM, Rello J, et al. Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest. 2010;137:552–7.
PubMed
Google Scholar
Restrepo MI, Mortensen EM, Velez JA, et al. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest. 2008;133:610–7.
PubMed
Google Scholar
Wiseman LR, Wagstaff AJ, Brogden RN, et al. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1995;50:73–101.
CAS
PubMed
Google Scholar
Dhillon S. Meropenem/vaborbactam: a review in complicated urinary tract infections. Drugs. 2018;78:1259–70.
CAS
PubMed
PubMed Central
Google Scholar
Jaruratanasirikul S, Thengyai S, Wongpoowarak W, et al. Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units. Antimicrob Agents Chemother. 2015;59:2995–3001.
CAS
PubMed
PubMed Central
Google Scholar
Ramon-Lopez A, Allen JM, Thomson AH, et al. Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations. J Antimicrob Chemother. 2015;70:882–90.
CAS
PubMed
Google Scholar
Zhou QT, He B, Shen N, et al. Meropenem dosing based on a population pharmacokinetic-pharmacodynamic model in elderly patients with infection of the lower respiratory tract. Drugs Aging. 2017;34:115–21.
CAS
PubMed
Google Scholar
Conte JE Jr, Golden JA, Kelley MG, et al. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem. Int J Antimicrob Agents. 2005;26:449–56.
CAS
PubMed
Google Scholar
Cies JJ, Moore WS 2nd, Enache A, et al. Population pharmacokinetics and pharmacodynamic target attainment of meropenem in critically ill young children. J Pediatr Pharmacol Ther. 2017;22:276–85.
PubMed
PubMed Central
Google Scholar
Usman M, Frey OR, Hempel G. Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal function. Eur J Clin Pharmacol. 2017;73:333–42.
CAS
PubMed
Google Scholar
Alobaid AS, Wallis SC, Jarrett P, et al. Effect of obesity on the population pharmacokinetics of meropenem in critically ill patients. Antimicrob Agents Chemother. 2016;60:4577–84.
CAS
PubMed
PubMed Central
Google Scholar
Doh K, Woo H, Hur J, et al. Population pharmacokinetics of meropenem in burn patients. J Antimicrob Chemother. 2010;65:2428–35.
CAS
PubMed
Google Scholar
Hanberg P, Öbrink-Hansen K, Thorsted A, et al. Population pharmacokinetics of meropenem in plasma and subcutis from patients on extracorporeal membrane oxygenation treatment. Antimicrob Agents Chemother. 2018;62:e02390.
CAS
PubMed
PubMed Central
Google Scholar
Kristoffersson AN, David-Pierson P, Parrott NJ, et al. Simulation-based evaluation of PK/PD indices for meropenem across patient groups and experimental designs. Pharm Res. 2016;33:1115–25.
CAS
PubMed
Google Scholar
Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14:498–509.
PubMed
PubMed Central
Google Scholar
Mendez A, Chagastelles P, Palma E, et al. Thermal and alkaline stability of meropenem: degradation products and cytotoxicity. Int J Pharm. 2008;350:95–102.
CAS
PubMed
Google Scholar
Jaruratanasirikul S, Sriwiriyajan S. Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection. J Antimicrob Chemother. 2003;52:518–21.
CAS
PubMed
Google Scholar
McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents. 2008;31:345–51.
CAS
PubMed
Google Scholar
Tam VH, McKinnon PS, Akins RL, et al. Pharmacodynamics of cefepime in patients with gram-negative infections. J Antimicrob Chemother. 2002;50:425–8.
CAS
PubMed
Google Scholar
Abdul-Aziz MH, Lipman J, Akova M, et al. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. J Antimicrob Chemother. 2016;71:196–207.
CAS
PubMed
Google Scholar
Veiga RP, Paiva JA. Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients. Crit Care (Lond, Engl). 2018;22:233.
Google Scholar
Kazmierczak KM, Karlowsky JA, de Jonge BLM, et al. Epidemiology of carbapenem resistance determinants identified in meropenem-nonsusceptible enterobacterales collected as part of a global surveillance program, 2012 to 2017. Antimicrob Agents Chemother. 2021;65:e0200020.
PubMed
Google Scholar
Hassuna NA, Darwish MK, Sayed M, et al. Molecular epidemiology and mechanisms of high-level resistance to meropenem and imipenem in Pseudomonas aeruginosa. Infect Drug Resist. 2020;13:285–93.
CAS
PubMed
PubMed Central
Google Scholar
Sharma M, Singhal L, Gautam V, et al. Distribution of carbapenemase genes in clinical isolates of Acinetobacter baumannii & a comparison of MALDI-TOF mass spectrometry-based detection of carbapenemase production with other phenotypic methods. Indian J Med Res. 2020;151:585–91.
PubMed
PubMed Central
Google Scholar
Shahbaz H, Gupta M. Creatinine clearance. StatPearls. Treasure Island (FL): StatPearls Publishing. Copyright © 2021, StatPearls Publishing LLC., 2021.
Nunes MBG, Filho AC, Alvares VRC, et al. CKD-EPI versus Cockcroft-Gault formula for predicting contrast-induced nephropathy following percutaneous coronary intervention in patients without significant renal impairment. Rev Port Cardiol. 2018;37:25–33.
PubMed
Google Scholar
Casals G, Hernández C, Hidalgo S, et al. Development and validation of a UHPLC diode array detector method for meropenem quantification in human plasma. Clin Biochem. 2014;47:223–7.
CAS
PubMed
Google Scholar
Zou L, Meng F, Hu L, et al. A novel reversed-phase high-performance liquid chromatographic assay for the simultaneous determination of imipenem and meropenem in human plasma and its application in TDM. J Pharm Biomed Anal. 2019;169:142–50.
CAS
PubMed
Google Scholar
Wong G, Farkas A, Sussman R, et al. Comparison of the accuracy and precision of pharmacokinetic equations to predict free meropenem concentrations in critically ill patients. Antimicrob Agents Chemother. 2015;59:1411–7.
PubMed
PubMed Central
Google Scholar
Zhao W, Kaguelidou F, Biran V, et al. External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings. Br J Clin Pharmacol. 2013;75:1068–80.
CAS
PubMed
Google Scholar
Glen JB, Servin F. Evaluation of the predictive performance of four pharmacokinetic models for propofol. Br J Anaesth. 2009;102:626–32.
CAS
PubMed
Google Scholar
Egi A, Fukuda H, Kawamoto M, et al. Preoperative prediction of creatinine clearance by using serum creatinine. Masui Jpn J Anesthesiol. 2004;53:1306–10.
Google Scholar
Chung EK, Cheatham SC, Fleming MR, et al. Population pharmacokinetics and pharmacodynamics of meropenem in nonobese, obese, and morbidly obese patients. J Clin Pharmacol. 2017;57:356–68.
CAS
PubMed
Google Scholar
Sjövall F, Alobaid AS, Wallis SC, et al. Maximally effective dosing regimens of meropenem in patients with septic shock. J Antimicrob Chemother. 2018;73:191–8.
PubMed
Google Scholar
Benítez-Cano A, Luque S, Sorlí L, et al. Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial. Crit Care (Lond, Engl). 2020;24:55.
Google Scholar
Burger R, Guidi M, Calpini V, et al. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections. J Antimicrob Chemother. 2018;73:3413–22.
CAS
PubMed
Google Scholar
Corcione S, D’Avolio A, Loia RC, et al. Pharmacokinetics of meropenem in burn patients with infections caused by Gram-negative bacteria: are we getting close to the right treatment? J Glob Antimicrob Resist. 2020;20:22–7.
PubMed
Google Scholar
Chytra I, Stepan M, Benes J, et al. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care (Lond, Engl). 2012;16:R113.
Google Scholar
Wang Z, Shan T, Liu Y, et al. Comparison of 3-hour and 30-minute infusion regimens for meropenem in patients with hospital acquired pneumonia in intensive care unit: a randomized controlled clinical trial. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2014;26:644–9.
PubMed
Google Scholar
Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2021;21:213–25.
CAS
PubMed
Google Scholar
Nguyen CP, Dan-Do TN, Bruggemann R, et al. Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs meropenem for Gram-negative infections: a systematic review, meta-analysis, and cost-effectiveness analysis. Int J Antimicrob Agents. 2019;54:790–7.
CAS
PubMed
Google Scholar
Ehmann L, Zoller M, Minichmayr IK, et al. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis. Int J Antimicrob Agents. 2019;54:309–17.
CAS
PubMed
Google Scholar
Roberts JA, Udy AA, Jarrett P, et al. Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients. J Antimicrob Chemother. 2015;70:1495–502.
CAS
PubMed
Google Scholar
Motos A, Kuti JL, Li Bassi G, et al. Is one sample enough? β-lactam target attainment and penetration into epithelial lining fluid based on multiple bronchoalveolar lavage sampling time points in a swine pneumonia model. Antimicrob Agents Chemother. 2019;63:e01922.
CAS
PubMed
PubMed Central
Google Scholar
Neely MN, van Guilder MG, Yamada WM, et al. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit. 2012;34:467–76.
PubMed
PubMed Central
Google Scholar